Concord Biotech Reports Q1 Financial Results with Revenue of Rs 27.03 Cr
Concord Biotech Limited has released its unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. The results were reviewed by Statutory Auditors BSR & Co. LLP.The company's performance showed variations across segments, with consolidated income reaching Rs 27,031.49 lakhs, while standalone total income stood at Rs 27,361.35 lakhs for the quarter. The Board of Directors approved these results following a meeting held on July 31, 2026.
Financial Performance Overview (Consolidated)
The consolidated statements detail the company's financial activity across its parent and subsidiaries. Total income from operations for the first quarter stood at Rs 25,748.90 lakhs. Key expenses included Cost of materials consumed at Rs 6,985.45 lakhs and Employee benefits expense at Rs 4,363.81 lakhs.The financial performance metrics for the consolidated entity are summarized below:
| Particulars | Q ended 30-Jun-26 (Unaudited) | Q ended 31-Mar-26 | Q ended 30-Jun-25 (Unaudited) | Y ended 31-Mar-26 (Audited) |
|---|---|---|---|---|
| Total Income | 27,031.49 lakhs | 34,142.90 lakhs | 21,766.52 lakhs | 1,10,724.60 lakhs |
| Cost of materials consumed | 6,985.45 lakhs | 7,054.09 lakhs | 5,990.99 lakhs | 25,434.78 lakhs |
| Total Expenses | 19,324.91 lakhs | 22,717.60 lakhs | 16,042.57 lakhs | 76,223.26 lakhs |
| Profit before tax and share of joint venture | 7,706.58 lakhs | 11,425.30 lakhs | 5,723.95 lakhs | 34,173.80 lakhs |
| Profit after tax for the period | 5,769.69 lakhs | 8,846.69 lakhs | 4,405.78 lakhs | 25,922.91 lakhs |
Standalone Results and Operational Updates
In the standalone results, total income from operations for Concord Biotech Limited stood at Rs 26,051.71 lakhs. Total expenses were recorded at Rs 19,140.39 lakhs, leading to a profit after tax of Rs 6,119.37 lakhs.The company's standalone performance metrics are detailed as follows:
| Particulars | Q ended 30-Jun-26 (Unaudited) | Q ended 31-Mar-26 | Q ended 30-Jun-25 (Unaudited) | Y ended 31-Mar-26 (Audited) |
|---|---|---|---|---|
| Total Income | 27,361.35 lakhs | 34,143.37 lakhs | 21,766.52 lakhs | 1,10,780.16 lakhs |
| Cost of materials consumed | 6,985.45 lakhs | 7,054.09 lakhs | 5,990.99 lakhs | 25,434.78 lakhs |
| Total Expenses | 19,140.39 lakhs | 22,305.61 lakhs | 16,042.57 lakhs | 75,309.44 lakhs |
| Profit before tax (after exceptional items) | 8,220.96 lakhs | 11,837.76 lakhs | 5,723.95 lakhs | 35,143.18 lakhs |
| Profit after tax for the period | 6,119.37 lakhs | 9,002.21 lakhs | 4,256.55 lakhs | 26,326.67 lakhs |
Key Business Developments
Notes accompanying the financial statements confirmed several material operational and accounting updates for the period:- Labour Code Impact: The Group recognized an incremental liability of Rs 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under new Labour Codes notified by the Government of India in November 2025. This impact was disclosed under exceptional items for the financial year ended March 31, 2026.
- Acquisition: Celliimune Biotech Private Limited, incorporated on January 15, 2025, was acquired by Concord Biotech Limited as of April 02, 2026, making it a wholly owned subsidiary since that date.
The consolidated results reviewed various entities including Concord Lifegen Limited (wholly owned subsidiary), Celliimune Biotech Private Limited (wholly owned subsidiary), Stellon Biotech Inc. (Subsidiary), and Concord Biotech Japan K.K. (Joint Venture).
CONCORDBIO Stock Price Movement
Today, shares of Concord Biotech Limited edged significantly higher as the stock closed post-market trading, gaining 6.76% to reach ₹1420.8. The equity saw a trading range between a low of ₹1333 and a high of ₹1429.4, with a total volume of 598,564 shares traded today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: